3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
14
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Microsatellite Instability
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Gastroesophageal Cancer
1
Interventions
pembrolizumab
3
atezolizumab
2
Sugammadex
2
Saline Solution
2
Paclitaxel
2
Neostigmine
2
Gemcitabine
2
Cetuximab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
lenvatinib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
delta 24-sterol reductase
1
daratumumab
1
cabozantinib
1
abemaciclib
1
Zoledronic Acid
1
Water
1
Valproic Acid
1
Urinary Diversion
1
Ultrasonography
1
Trastuzumab
1
Tomography, Optical Coherence
1
Tissue Banks
1
Therapeutics
1
Testosterone Propionate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled